Post-marketing safety profile of bictegravir/emtricitabine/tenofovir alafenamide: a FAERS pharmacovigilance study with EudraVigilance validation and mechanistic investigation of pancreatitis

Yuxin Xie, Yawen Luo, Yinghua Chen, Guoqing Shi, Yihuai He, Xia Liu, Zhiwei Cui, Fan Zou, Chengyu Zhu · 2026

Read Post-marketing safety profile of bictegravir/emtricitabine/tenofovir alafenamide: a FAERS pharmacovigilance study with EudraVigilance validation and mechanistic investigation of pancreatitis by Yuxin Xie, Yawen Luo, Yinghua Chen, Guoqing Shi, Yihuai He, Xia Liu, Zhiwei Cui, Fan Zou, Chengyu Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13435438.txt.

Description

Yuxin Xie's team mined safety reports in 2026 for a first-line HIV regimen combining bictegravir, emtricitabine, and tenofovir alafenamide. Long-term real-world safety data were thin. The team analyzed 5,815 adverse event reports in the FAERS database from 2018 to 2025, validated key signals in EudraVigilance, and probed one surprise signal, pancreatitis, with added models and lab data.

Known effects like weight gain, headache, and immune reconstitution syndrome appeared as expected, while pancreatitis emerged as an unexpected signal worth watching. Sex, timing, and sensitivity checks were run to test how firm the signals were. HIV clinicians get a large post-market safety map, with pancreatitis flagged for vigilance rather than proven as caused by the drugs.

Catalog record

CREATORYuxin Xie, Yawen Luo, Yinghua Chen, Guoqing Shi, Yihuai He, Xia Liu, Zhiwei Cui, Fan Zou, Chengyu Zhu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE94 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13435438

Browse the full library · About the Tower of Babel